Hyperfine (HYPR) Q4 2025 earnings review
The "Tale of Two Halves" Materializes with Massive Q4 Inflection
Hyperfine's management staked their credibility on a second-half 2025 commercial inflection, and Q4 results emphatically delivered. Revenue surged 128% YoY to $5.29M, driven by the rollout of the higher-priced Next-Generation Swoop scanner. The pricing power on this new hardware is striking: full-year device revenue grew 9% despite a 21% drop in total units sold. Gross margins expanded to 51% in Q4 (up from 36% a year ago). A newly secured $40M term loan in March 2026 extends the cash runway into 2028, removing near-term liquidity overhangs. With FY26 revenue guidance calling for 55% growth at the midpoint, the company has successfully transitioned from a stalled hospital-only story into a multi-channel commercial growth phase.
🐂 Bull Case
The Next-Gen Swoop launch drove a massive increase in average selling price (ASP). FY25 device revenue climbed 9.1% to $11.4M despite total unit sales dropping from 48 to 38, directly fueling the Q4 gross margin expansion to 51%.
Ending 2025 with $35.1M in cash, Hyperfine secured a $40M credit facility in March 2026 ($15M initially funded). Combined with a 10% forecasted drop in FY26 cash burn, the company's runway now extends into 2028.
🐻 Bear Case
Despite a growing installed base, Service revenue declined 11.3% YoY. Management admitted this was due to transitioning customers to "new service and support contracts at a lower annual price," indicating a lack of pricing power on the recurring revenue side.
The company remains entirely reliant on a single supplier in Europe for the proprietary magnet in the Swoop system, exposing them to geopolitical and tariff-related supply chain shocks.
⚖️ Verdict: 🟢
Bullish. The commercial pivot is working. Hyperfine delivered the exact Q4 acceleration it promised, expanded gross margins significantly, and secured non-dilutive capital to fund its aggressive FY26 growth targets.
Key Themes
Next-Gen Hardware Drives Margin Expansion
The Next-Gen Swoop scanner and Optive AI software fundamentally improved unit economics. While FY25 unit volume dropped 20.8% YoY (38 units vs 48 units), device revenue actually grew 9.1%. This implied ASP spike pulled Q4 gross margins up to 51% from 36% a year prior. Management's bet that superior image quality would command a premium is paying off.
Recurring Revenue Takes a Step Backward
A notable red flag buried in the 10-K: Service revenue decelerated, falling 11.3% YoY to $2.16M. Management explicitly cited the "expiration of the subscription service contracts from prior years and the transition to new service and support contracts at a lower annual price." While the company has pricing power on the box, they are struggling to maintain premium pricing on the recurring SaaS/maintenance tail.
Multi-Channel Expansion Validated
The Q4 surge to 16 unit sales (up from 9 in 24Q4) validates the pivot away from relying solely on hospital critical care units. The launch into the outpatient Neurology Office setting—aided by new IAC accreditation standards allowing for CMS reimbursement—is expanding the addressable market and driving immediate volume.
Aggressive Cost Restructuring Yields Results
Operating leverage is beginning to show. The 14% global workforce reduction enacted in January 2025 successfully brought down R&D expenses by 22.4% ($5.0M) and General & Administrative expenses by 7.1% ($1.2M) for the full year. This discipline reduced operating cash burn by nearly $11M YoY down to $27.9M.
Other KPIs
Accelerating improvement. The net loss narrowed significantly from -$10.39 million in 24Q4. While aided by a $1.46M non-cash gain on warrant liabilities, the core improvement was driven by higher gross profit ($2.69M vs $0.83M) and strictly managed operating expenses.
Improving. Cash used in operations fell from -$38.7M in FY24. With $35.1M in cash on the balance sheet and a newly secured $40M term loan facility ($15M drawn immediately in March 2026), the company's liquidity position is secure into 2028.
Guidance
Accelerating dramatically. The $21M midpoint implies 55% YoY growth, a massive step up from the 5.2% growth achieved in FY25. This suggests high confidence that the Q4 run-rate ($5.29M) is the new baseline floor for the coming year.
Stable. The $27M midpoint represents a 10% decline from FY25 cash burn. Management is telegraphing that they can fund the 55% top-line revenue growth through existing operating leverage rather than requiring a corresponding spike in cash burn.
Key Questions
Service Contract Pricing
Service revenue fell 11% this year due to transitioning customers to lower-priced annual contracts. Is this lower price point the new permanent baseline to secure renewals, and how does this alter the long-term margin profile of the installed base?
Guidance Cadence
Your FY26 revenue guidance of $20-$22M implies an average of ~$5.25M per quarter. Given you already achieved $5.29M in Q4, does your guidance assume flat sequential growth throughout 2026, or is there seasonality we should model?
Unit Mix
Of the 16 commercial systems sold in Q4, what was the exact split between traditional hospital environments and the newly launched Neurology Office setting?